Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Biostar Pharma to Develop Liver Cancer Drug with Shaanxi University

publication date: Mar 7, 2014
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Biostar Pharma, a China maker of pharmaceuticals and health supplements, signed a letter of intent to develop Oleanolic acid injection as a treatment for liver cancer with Shaanxi University of Chinese Medicine. Biostar’s best-selling product is its Xin Aoxing Oleanolic Acid Capsule, an OTC medicine for chronic hepatitis B. Terms of the proposed deal were not disclosed, but Biostar did say it was prepared to invest a large amount of capital and resources into the project. More details....

Stock Symbol: (NSDQ: BSPM)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors